BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Price

BTAIStock

$0.74−84.73%52W

Market Cap$23.23M

P/E—

PEG Ratio—

Div yield—

Beta0.37

BTAI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-63.11%

Price vs S&P 500 (4W)-13.04%

VGM Score24.74

Book Value / Share (Quarterly)$0.20

P/TBV (Annual)1.50x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)19.10%

Cash Flow / Share (Quarterly)$-2.12

Price vs S&P 500 (YTD)-64.42%

Gross Margin (TTM)36.32%

Net Profit Margin (TTM)-11078.53%

EPS (TTM)$-5.74

10-Day Avg Trading Volume1.33M

EPS Excl Extra (TTM)$-5.74

EPS (Annual)$-5.73

ROI (Annual)-97.56%

Gross Margin (Annual)74.45%

Net Profit Margin (5Y Avg)-108558.70%

Cash / Share (Quarterly)$0.63

Revenue Growth QoQ (YoY)22.62%

ROA (Last FY)-155.62%

Revenue Growth TTM (YoY)-63.28%

EBITD / Share (TTM)$-2.98

ROE (5Y Avg)-95.18%

Operating Margin (TTM)-7438.97%

Cash Flow / Share (Annual)$-2.58

P/B Ratio5.94x

P/B Ratio (Quarterly)32.92x

Net Income / Employee (Annual)$-2,410,200

EV / Revenue (TTM)173.76x

Net Interest Coverage (TTM)-3.39x

ROA (TTM)-201.53%

EPS Incl Extra (Annual)$-5.73

Current Ratio (Annual)0.83x

Quick Ratio (Quarterly)0.54x

3-Month Avg Trading Volume0.93M

52-Week Price Return-84.73%

Revenue / Employee (TTM)$23,400

Tangible BV / Share (Quarterly)$-1.39

P/S Ratio (Annual)54.59x

Asset Turnover (Annual)0.01x

52-Week High$5.60

Operating Margin (5Y Avg)-107317.30%

EPS Excl Extra (Annual)$-5.73

26-Week Price Return-51.86%

Quick Ratio (Annual)0.74x

13-Week Price Return-33.28%

Total Debt / Equity (Annual)1.21x

Current Ratio (Quarterly)0.62x

Enterprise Value$118.16M

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$22,100

Inventory Turnover (Annual)0.23x

Pretax Margin (Annual)-10887.38%

Cash / Share (Annual)$1.27

3-Month Return Std Dev114.27%

Net Income / Employee (TTM)$-2,597,700

ROE (Last FY)-215.83%

Net Interest Coverage (Annual)-3.65x

EPS Basic Excl Extra (Annual)$-5.73

Receivables Turnover (TTM)6.30x

Total Debt / Equity (Quarterly)16.41x

EPS Incl Extra (TTM)$-5.74

Receivables Turnover (Annual)3.53x

ROI (TTM)-126.96%

P/S Ratio (TTM)51.54x

Pretax Margin (5Y Avg)-108558.70%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$2.73

Price vs S&P 500 (52W)-103.04%

Year-to-Date Return-52.46%

5-Day Price Return-3.98%

EPS Normalized (Annual)$-5.73

ROA (5Y Avg)-135.84%

Net Profit Margin (Annual)-10887.38%

Month-to-Date Return-5.87%

Cash Flow / Share (TTM)$-7.34

EBITD / Share (Annual)$-4.11

Operating Margin (Annual)-7859.97%

LT Debt / Equity (Annual)1.21x

ROI (5Y Avg)-71.53%

LT Debt / Equity (Quarterly)16.41x

EPS Basic Excl Extra (TTM)$-5.74

P/B Ratio (Annual)7.84x

Inventory Turnover (TTM)0.76x

Pretax Margin (TTM)-11078.53%

Book Value / Share (Annual)$2.73

Price vs S&P 500 (13W)-36.07%

Beta0.37x

Revenue / Share (TTM)$0.03

ROE (TTM)-309.01%

52-Week Low$0.74

vGradeD

gGradeD

mGradeF

vgmGradeD

BTAI Earnings Surprise History

Q2 25-2.45est. -1.56

Q3 25-2.16est. -1.34

Q1 26-0.54est. -0.48

Q2 26-0.49est. -0.58

BTAI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.91

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
BTAIBioXcel Therapeutics, Inc. Common Stock	D	D	F	$0.74
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About BioXcel Therapeutics, Inc. Common Stock

BioXcel Therapeutics develops neuropsychiatric and immuno-oncology medicines using artificial intelligence platforms. Its FDA-approved commercial product, IGALMI, is a sublingual dexmedetomidine film for acute agitation associated with schizophrenia and bipolar I or II disorder in adults. The company is advancing additional pipeline candidates including BXCL701.